d7bbb44a-3fe0-4455-99d0-90be213f2a31
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.470
- WNT_BETA_CATENIN_SIGNALING+0.410
- KRAS_SIGNALING_DN+0.400
- MYOGENESIS+0.360
- PANCREAS_BETA_CELLS+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- APICAL_JUNCTION+0.210
- UV_RESPONSE_DN+0.140
- ANGIOGENESIS+0.120
- NOTCH_SIGNALING+0.100
Top 10 suppressed
- MYC_TARGETS_V1-0.580
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V2-0.570
- MTORC1_SIGNALING-0.500
- PROTEIN_SECRETION-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- E2F_TARGETS-0.480
- TNFA_SIGNALING_VIA_NFKB-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.420
- GLYCOLYSIS-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR33346962 | — | — | 0.934 |
| 2 | SRR23303745 | — | — | 0.928 |
| 3 | X84315f98.9366.4174.be54.3cdd1fd9db07 | — | cohortA1 | 0.914 |
| 4 | d2995480-5ae0-42e1-9a21-25e1435201ee | — | — | 0.907 |
| 5 | BS_4W68NV3M | Med | Medulloblastoma | 0.894 |
| 6 | SRR1313107 | — | F | 0.891 |
| 7 | BS_CZ82ANWP | DNET | — | 0.888 |
| 8 | SRR1313172 | — | A | 0.887 |
| 9 | a545f8c1-39e3-48cc-8c22-897c5d3a21ea | — | — | 0.879 |
| 10 | MNG690 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |